bacterial strain News
-
Fluorescence Immunoassay for Detection of Pathogens
Listeriosis is a foodborne infectious disease caused by the pathogen Listeria monocytogenes and is particularly serious for pregnant women and immunocompromised persons. The pathogen is spread mainly through spoiled and contaminated food or animal feed. Methods for the detection of Listeria monocytogenes (LM) on surfaces in the food industry have been developed to control the spread of the ...
-
Infant Bacterial Therapeutics publishes Annual Report for 2021
Infant Bacterial Therapeutics AB (publ) publishes today the Annual Report for 2021. The report is available on IBT’s website ibtherapeutics.com under the section “Investors & Media – Financial Reports” and is available in printed form for those that have requested. A copy can be requested by contacting IBT’s office via info@ibtherapeutics.com. About Infant ...
-
Recruitment of the smallest infants in the Connection study paused
IBT started to recruit infants in Strata A (weight of 500g-749g) in The Connection Study on April 29 2021. Today, 68 infants have been recruited to the group. In accordance with the study protocol and clinical observations, enrolment of infants to Strata A has been paused awaiting a safety review by the Data Monitoring Committee (DMC). Subjects already randomized will continue treatment as per ...
-
Infant Bacterial Therapeutics receives additional patent protection in China
Infant Bacterial Therapeutics AB (IBT) today announces that the Chinese patent office has issued a decision to grant approval of IBTs patent application entitled: A method of activating lactic acid bacteria, which protects formulations of Lactobacillus reuteri including IBP-9414. IBT is currently developing its drug candidate IBP-9414 in Phase III for the prevention of NEC and improvement of ...
-
ID Genomics Awarded Prestigious Longitude Prize Discovery Award
Today, Seattle-based ID Genomics, Inc.was awarded a grant from the Longitude Prize Discovery Awards, a seed funding program to help teams competing to win the prestigious Longitude Prize. Run by innovation foundation Nesta and supported by Innovate UK as funding partner, the Longitude Prize is a £10 million prize fund to create a cost-effective, rapid and easy-to-use diagnostic test for ...
-
Biofabri and Probisearch sign an agreement with Casen Recordati for the development and production of new probiotics
The biotechnology companies Biofabri and Probisearch, members of the group formed by Biofabri and CZ Veterinaria, reached an agreement last October with Casen Recordati, the Spanish subsidiary of the Italian pharmaceutical company Recordati, for the clinical and industrial development and subsequent production of two innovative probiotics in the field of Pediatrics and women’s health. By ...
-
Annual General Meeting of Infant Bacterial Therapeutics
At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 4, 2022, among other things, the following was resolved: to adopt the income statement and balance sheet and the consolidated income statement and consolidated balance sheet; that no dividend is made; discharge from liability granted to Board members and the managing director, that the Board shall consist of ...
-
Intus Bio’s Software Update Enables High-throughput Microbiome Profiling of Known and Unknown Microbial Strains
Intus Biosciences, a microbiome research company with multi-platform, easy to use, ‘Sample-to-Answer’ products for characterizing microbiome populations down to the strain level, announces a significant update to its SBanalyzer software. Intus Biosciences SBanalyzer software enables discovery of never before detected species and strains from microbiome samples. In addition, ...
-
MicrobioSeq’s Plasmid Identification Service Boosts Microbial Characterization Research
MicrobioSeq is the microbial genomics division on behalf of CD Genomics, headquartered in New York, USA. CD Genomics is a genomics service company with a renowned reputation for providing reliable sequencing, genotyping, microarray, and bioinformatics services. The product manager is pleased to announce the launch of the Plasmid Identification service, thus helping researchers to efficiently ...
By CD Genomics
-
Osel’s Live Biotherapeutic Product Demonstrates Efficacy in Phase 2b Study of Bacterial Vaginosis
Osel, Inc., a company developing live biotherapeutic products (LBPs) for diseases linked to the disruption of the human microbiome, today announced clinical data showing that the company’s LACTIN-V LBP significantly reduced the recurrence of bacterial vaginosis (BV) vs. placebo in a Phase 2b trial. Results were published in the New England Journal of Medicine: “Randomized Trial of ...
By Osel Inc.
-
Artugen Therapeutics Announces First Patient Dosed with ART24, Artugen`s first clinical product candidate for prevention of recurrence of Clostridium difficile infection
ART24 granted Fast Track Designation First Patient Dosed Concord, Mass., and Dublin, Ireland March 12, 2020 — Artugen Therapeutics Limited, a Company developing novel live biotherapeutics (LBPs) for patients living with infectious, inflammatory and oncologic diseases announced today the first patient dosed with ART24, the Company’s first clinical product candidate for prevention ...
-
Osel Announces Positive Results from Phase 1b Trial of Live Biotherapeutic Product CBM588 in Combination with Checkpoint Inhibitor (CPI) Therapy in Metastatic Renal Cell Carcinoma
Osel Inc., a company developing live biotherapeutic products (LBPs) for diseases linked to the disruption of the human microbiome, announced today that City of Hope, a world-renowned independent cancer and diabetes research and treatment center, presented data from a Phase 1b trial showing that an LBP, CBM588 (Clostridium butyricum MIYAIRI 588® strain), plus nivolumab/ipilimumab improved ...
By Osel Inc.
-
City of Hope and Osel Announce Exclusive License for Intellectual Property on the use of Live Biotherapeutic Product CBM588 for Oncology Therapeutic Applications
City of Hope®, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases, and Osel, Inc., a company developing live biotherapeutic products (LBPs) for diseases linked to the disruption of the human microbiome, today announced that City of Hope has granted an exclusive worldwide license to Osel for intellectual property on the novel use ...
By Osel Inc.
-
LISCure Biosciences Announces Research Collaboration with The Scripps Research Institute for Immuno-Oncology
LISCure Biosciences ("LISCure") announced that it had reached an agreement with The Scripps Research Institute ("Scripps Research") to collaboratively research on bacteria-mediated immuno-oncology candidates against multiple cancer types. Scripps Research is the top nonprofit scientific institute in the US for producing high-quality research based on discoveries published in leading scientific ...
-
The transformation of precision medicine in infectious disease
Before Alexander Fleming discovered penicillin, another more selective antibacterial agent rose to popularity in the early 1900s: bacteriophage. In 1917, microbiologist Felix d’Herelle was tasked with identifying the cause of a dysentery outbreak impacting French troops. From his research, he noticed that Shigella bacteria was the primary culprit of this affliction. He then discovered an ...
-
Intestinal Inflammation in Infants Dramatically Reduced with Bifidobacterium infantis
Findings from a new study published today in Pediatric Research show that feeding activated Bifidobacterium infantis (B. infantis) EVC001 to breastfed infants reduced markers of chronic intestinal inflammation by up to 98 percent during the first two months of life, which is a critical period of immune system development. The study was led by researchers from The University of California, Davis ...
-
Recent microbiome study finds that Intus Bio’s products differentiate closely related gut bacteria in premature infants
Products from Intus Biosciences demonstrated high-resolution tracking of specific bacterial strains in a recent microbiome study, the results of which are being applied to better understand how pathogens and commensals become established in premature infants in neonatal intensive care units (NICU), with the goal of improving outcomes for premature infants. Intus Biosciences is a microbiome ...
-
City of Hope and Osel Announce Live Biotherapeutic Product CBM588 May Enhance Efficacy of Immunotherapy for Patients With Metastatic Kidney Cancer
City of Hope, one of the largest cancer research and treatment organizations in the United States, and Osel Inc., a company developing live biotherapeutic products for modulation of the human microbiome, today announced Phase 1 trial data showing that use of the live biotherapeutic CBM588 (Clostridium butyricum MIYAIRI 588® strain) plus immunotherapy medicine nivolumab/ipilimumab ...
By Osel Inc.
-
Vedanta Biosciences Presents New Data from Phase 1 Study of VE202, Its Rationally-Defined Consortium for the Treatment of Inflammatory Bowel Disease, at the International Human Microbiome Consortium Congress 2021 (IHMC)
Results further support the benign safety profile of VE202 and identify an optimal dosing regimen Vedanta plans to initiate a Phase 2 clinical trial of VE202 in ulcerative colitis patients in the second half of 2021 Vedanta Biosciences, a leading clinical-stage microbiome company developing a new category of oral therapies using defined bacterial consortia manufactured from clonal cell ...
-
NEC OncoImmunity Acquires VAXIMM’s Neoantigen Vaccine Development Assets
VAXIMM technology enables fast generation and delivery of personalized T-cell cancer vaccines and may overcome key issues faced by the neoantigen field NEC OncoImmunity to initiate first clinical trial with lead program from acquisition in 2022 Oslo (Norway)/Tokyo (Japan) and Basel (Switzerland)/Mannheim (Germany) - March 8, 2022: NEC OncoImmunity (NOI), a subsidiary of NEC Corporation ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you